期刊文献+

胃腺癌根治术后复发影响因素分析

Analysis of the risk factors of recurrence after curative resection for gastric adenocarcinoma
原文传递
导出
摘要 目的探讨胃腺癌根治术后早期复发和晚期复发的影响因素。方法回顾性分析214例胃腺癌根治术后复发患者临床资料,其中〈2年复发143例,≥2年复发71例,分析患者年龄、性别、肿瘤的部位、肿瘤的直径、肿瘤病理学分级、Borrmann分型、TNM分期、淋巴结转移、手术性质及术后有无辅助化疗等指标与胃腺癌复发的关系。结果单因素分析显示,肿瘤直径、Borrmann分型、TNM分期、淋巴结转移、手术性质和辅助化疗与术后复发时间有关(检验值分别为8.32、16.21、24.90、5.22、17.23和3.61,均P〈0.05);多因素分析显示,肿瘤直径和TNM分期是术后复发的独立因素(相对危险度分别为5.642和6.211,均P〈0.05)。结论肿瘤直径和TNM分期是影响胃腺癌根治术后复发的最重要的影响因素。 Objective To explore prognostic factors associated with early and late recurrences after surgery for patients with gastric adenocarcinoma. Methods 214 patients who underwent curative resection for gastric adeno-carcinoma were divided into 2 groups according to recurrence time : an early recurrence group included 143 patients who died within 2 years after surgery, and a late recurrence group included 71 patients who died more than 2 years after surgery. Indexes such as age, sex,tumor site,tumor size,tumor pathology classification, Borrmann type,TNM staging, lymph node metastasis, operation type and postoperative adjuvant chemotherapy were compared. Results Single factor analysis showed that the tumor diameter, Borrmann type, TNM staging, lymph node metastasis, operation type, adjuvant chemotherapy were asocciated with postoperative recurrence ( test value were 8.32,16.21,24.90,5.22, 17.23 and 3.61, respectively ; all P 〈 0.05 ). Muhifaetor analysis showed that tumor diameter and TNM staging is recurrent independent factors ( relative risk were 5. 642 and 6.211, respectively ; all P 〈 0.05 ). Conclusion Tumor size and TNM staging are the most important factors for predicting the timing of recurrence after curative resection for gastric adenocarcinoma. Clinical practice should pay attention to follow up for patients with tumor diameter≥5cm,TNM III-IV stage, especially within two years.
出处 《中国基层医药》 CAS 2012年第11期1626-1627,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 胃肿瘤 复发 危险因素 Stomach neplasms Recurrence Risk factors
  • 相关文献

参考文献3

二级参考文献41

  • 1李景武,梁寒,王晓娜.814例胃癌患者的预后因素分析[J].中国肿瘤临床,2006,33(7):399-402. 被引量:37
  • 2Houghtom J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone Marrow-Derived cells [ J ]. Science, 2004,306(5701) :1568 - 1571.
  • 3Lee SY, Hwang L, Park Ys, et al. Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes ? [ J ] . Int J Oncol , 2010,36(6) :1461 -1467.
  • 4Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice [J]. Gastric Cancer ,2010,13(1) : 1 - 10.
  • 5Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents .9 [ J ] . The Oncologist,2008,13(7) :794 -806.
  • 6Matsumoto S, Yamasaki K, Tsuji K, et al. Human T lymphotropic virus type 1 infection and gastric cancer development in Japan [ J ]. The Journal of Infectious Diseases , 2008,198 (1) :10-15.
  • 7Hitomi G, Watanabe H, Tominaga K, et al. Endoscopic submucosal dissection in 100 lesions with early gastric carcinoma [ J ]. Hepatogastroenterology, 2009 , 56 ( 89 ) : 254 - 260.
  • 8Heiyer LK, O'Brien C, Coburn NG. Surgeons' knowledge of quality indicators for gastric cancer surgery [ J ]. Gastric Cancer ,2007 ,(10) : 205 -214.
  • 9Jee YS, Hwang SH, Rao J, et al. Safety of extended endoscopic mucosal resection and endoscopic submucosal dissection following the Japanese Gastric Cancer Association treatment guidelines[J].Br J Surg, 2009 , 96 (10) : 1157 - 1161.
  • 10GASTRIC Group, Paoletti X, Oba K. Benefit of adjuvant chemotherapy for resectable gastric cancer a meta-analysis [J]. JAMA,2010,303(17) :1729 -1737.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部